ORIOMICS

Since its establishment, ORIOMICS has been deeply engaged in the research and development of non-invasive early screening and diagnosis technologies for digestive system tumors, striving to provide first-class early screening products for such cancers. Relying on a strong biotechnology and information analysis team, the company utilizes non-invasive cell-free DNA methylation detection technology in blood. With a multi-omics joint application platform and an innovative dual-layer machine learning analysis algorithm based on big data artificial intelligence, ORIOMICS has established a high-performance technical approach for early cancer screening and diagnosis. Leveraging years of big data accumulation in digestive system tumors, the company has successfully launched multiple single-cancer and multi-cancer joint detection products targeting the five most common cancers of the digestive system: liver cancer, stomach cancer, colorectal cancer, esophageal cancer, and pancreatic cancer. The performance of these products has reached a globally leading level. Adhering to the concept of making technology accessible to the public and serving health through technology, the company is guided by clinical needs, centers on customers, and aims to develop early cancer screening and diagnostic products with better performance, lower cost, and easier testing.